Last $37.72 USD
Change Today +0.36 / 0.96%
Volume 29.0K
BLUE On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 11:14 AM 10/22/14 All times are local (Market data is delayed by at least 15 minutes).

bluebird bio inc (BLUE) Snapshot

Open
$37.50
Previous Close
$37.36
Day High
$37.84
Day Low
$36.97
52 Week High
06/16/14 - $41.75
52 Week Low
11/20/13 - $17.03
Market Cap
1.1B
Average Volume 10 Days
338.6K
EPS TTM
$-1.18
Shares Outstanding
28.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for BLUEBIRD BIO INC (BLUE)

bluebird bio inc (BLUE) Related Bloomberg News

View More Bloomberg News

bluebird bio inc (BLUE) Related Businessweek News

No Related Businessweek News Found

bluebird bio inc (BLUE) Details

bluebird bio, Inc., a clinical-stage biotechnology company, focuses on developing gene therapies for severe genetic and orphan diseases. The company’s advanced product candidate is Lenti-D, which is in phase II/III studies for the treatment of childhood cerebral adrenoleukodystrophy, a rare, hereditary neurological disorder affecting young boys; and LentiGlobin that is in phase I/II studies for the treatment of beta-thalassemia major and severe sickle cell disease in France, as well as a second phase I/II studies with LentiGlobin for the treatment of beta-thalassemia major in the United States. bluebird bio, Inc. has a strategic collaboration with Celgene Corporation to discover, develop, and commercialize disease-altering gene therapies in oncology. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was founded in 1992 and is headquartered in Cambridge, Massachusetts.

102 Employees
Last Reported Date: 08/12/14
Founded in 1992

bluebird bio inc (BLUE) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $392.5K
Principal Financial Officer, Chief Operating ...
Total Annual Compensation: $321.7K
Chief Medical Officer
Total Annual Compensation: $305.5K
Chief Scientific Officer
Total Annual Compensation: $307.2K
Compensation as of Fiscal Year 2013.

bluebird bio inc (BLUE) Key Developments

bluebird bio, Inc. Announces First Patient with Sickle Cell Disease Transplanted with Lentiglobin Gene Therapy

bluebird bio, Inc. announced that the first subject with severe sickle cell disease has undergone infusion with bluebird bio's LentiGlobin BB305 drug product in an autologous hematopoietic stem cell transplantation. This patient is enrolled in the HGB-205 Study being conducted in Paris, France. bluebird has also opened a separate US-based trial (HGB-206) in the United States for the treatment of up to 8 severe sickle cell disease patients with the company's LentiGlobin BB305 drug product.

bluebird bio, Inc. Presents at Stem Cell Meeting on the Mesa Partnering Forum, Oct-07-2014 through Oct-09-2014

bluebird bio, Inc. Presents at Stem Cell Meeting on the Mesa Partnering Forum, Oct-07-2014 through Oct-09-2014. Venue: Estancia La Jolla Hotel & Spa, 9700 North Torrey Pines Road, La Jolla, CA 92037, United States. Presentation Date & Speakers: Oct-08-2014, Anne-Virginie Eggimann, VP, Regulatory Science, Faraz Ali, Head of Program Management & Commercial Development and Vice President.

bluebird bio, Inc. Presents at 13th Annual BIO Investor Forum, Oct-07-2014 through Oct-08-2014

bluebird bio, Inc. Presents at 13th Annual BIO Investor Forum, Oct-07-2014 through Oct-08-2014. Venue: The Palace Hotel, San Francisco, CA 94105, United States. Presentation Date & Speakers: Oct-07-2014, Nick Leschly, Chief Executive Officer, President and Director, Richard Morgan, PhD, Vice President, Immunotherapy.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BLUE:US $37.72 USD +0.36

BLUE Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Fibrocell Science Inc $3.11 USD 0.00
Sangamo BioSciences Inc $10.61 USD +0.09
View Industry Companies
 

Industry Analysis

BLUE

Industry Average

Valuation BLUE Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 35.5x
Price/Book 5.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 34.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BLUEBIRD BIO INC, please visit www.bluebirdbio.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.